Better Buy: Cara Therapeutics vs. Corbus Pharmaceuticals
As exciting as 2019 was for biotech investors, this upcoming year is gearing up to be possibly even more interesting, with many potential blockbuster drugs on the horizon. A number of these candidates have come from small-cap biotech companies with the chance of making big gains if they receive approval from the U.S. Food and Drug Administration.
Cara Therapeutics (NASDAQ: CARA) and Corbus Pharmaceuticals (NASDAQ: CRBP) fall into this category, with both companies showing strong clinical results for their flagship drug candidates. Let's see how these two biotech stocks stack up against each other, and which stock is the better buy today.
Image source: Getty Images.
Source Fool.com
